GlassScriptPhysician profile
Aleksandr Isakov
NPI 1902339153
$6,604.85
in general payments reported to CMS, 2019-2025
35 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $1,093 · 2023: $1,390 · 2024: $1,720 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.76 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,830.36 | 2022-2025 | |
| Abbott Laboratories | $591.28 | 2022 | |
| Boston Scientific Corporation | $587.86 | 2021 | |
| Sk Life Science, INC. | $486.71 | 2023-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $357.61 | 2022-2024 | Ingrezza, Ongentys |
| Argenx US, INC. | $353.28 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $310.61 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $250.53 | 2023-2025 | Ultomiris |
| Ucb, INC. | $229.55 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Emd Serono, INC. | $150.47 | 2022-2025 | Mavenclad |
| Pfizer INC. | $142.74 | 2023-2024 | |
| Medtronic, INC. | $135.82 | 2021 | |
| Janssen Biotech, INC. | $113.67 | 2025 | |
| Nevro Corp. | $91.08 | 2024 | Senza |
| Motiva USA, LLC | $88.60 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $83.98 | 2023-2025 | |
| Biogen, INC. | $79.70 | 2022-2024 | Vumerity |
| Otsuka America Pharmaceutical, INC. | $74.38 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $71.82 | 2024-2025 | |
| Lundbeck LLC | $69.18 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $58.64 | 2024-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $57.41 | 2022 | |
| Horizon Therapeutics Plc | $56.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $46.70 | 2023 | Onpattro |
| Spr Therapeutics, INC | $33.74 | 2024 | Sprint Pns System |
| Upsher-Smith Laboratories LLC | $31.33 | 2022 | |
| Merz Pharmaceuticals, LLC | $29.46 | 2025 | Inbrija |
| Mallinckrodt Hospital Products INC. | $29.13 | 2022 | |
| Collegium Pharmaceutical, INC. | $28.63 | 2022 | |
| Axsome Therapeutics, INC. | $28.15 | 2025 | Symbravo |
| Globus Medical, INC. | $26.38 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $25.00 | 2022 | |
| Ge Healthcare | $21.99 | 2025 | |
| Genentech USA, INC. | $18.47 | 2023 | |
| Vertos Medical, INC. | $13.97 | 2023 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Isakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.